Evaluation of A-azepano-triterpenoids and related derivatives as antimicrobial and antiviral agents
作者:Oxana Kazakova、Elena Tret’yakova、Dmitry Baev
DOI:10.1038/s41429-021-00448-9
日期:2021.9
hydrazido/hydrazono-substituents at C3 and C28 has been synthesized and evaluated for antimicrobial activity against key ESKAPE pathogens and DNA viruses (HSV-1, HCMV, HPV-11). It was found that azepanouvaol 8, 3-amino-3,4-seco-4(23)-en derivatives of uvaol 21 and glycyrrhetol-dien 22 as well as azepano-glycyrrhetol-tosylate 32 showed strong antimicrobial activities against MRSA with MIC ≤ 0.15 μM that exceeds the
organic nitrogen-containing heterocyclic compound with a 1,2,3-Triazole ring. In order to develop a potential glucosamine-6-phosphate synthase (GlmS) inhibitor bactericide, 18 triazole-derivative compounds were synthesized efficiently. In addition, these compounds have not been reported in the literature. The structure was confirmed by high-resolution mass spectrometry (HRMS), 1H NMR and 13C NMR. The
A series of novel substituted pyrazole-fused oleanolic acid derivative were synthesized and evaluated as selective α-glucosidase inhibitors. Among these analogs, compounds 4a–4f exhibited more potent inhibitory activities compared with their methyl ester derivatives, and standard drugs acarbose and miglitol as well. Besides, all these analogs exhibited good selectivity towards α-glucosidase over α-amylase
USE OF PENTACYCLIC TRITERPENE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOUND INTENDED FOR THE TREATMENT OF MULTIPLE SCLEROSIS
申请人:Consejo Superior De Investigaciones Científicas
公开号:EP2260851A1
公开(公告)日:2010-12-15
The invention relates to the use of pentacyclic triterpene for the preparation of a pharmaceutical compound intended for the treatment of multiple sclerosis. Oleanolic acid (3ss-hydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene acid present in a large number of medicinal plants. The invention relates to the pharmacological use of oleanolic acid either alone or combined with other substances in the therapy or prophylaxis of neurodegenerative diseases, such as multiple sclerosis. The applicants have found that the daily intraperitoneal administration of oleanolic acid significantly reduces the neurological and immunoinflammatory symptoms associated with experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, delaying the onset and reducing the progression of the disease
PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF
申请人:Chengdu Kanghong Pharmaceutical Co., Ltd.
公开号:EP2431041A1
公开(公告)日:2012-03-21
The present invention provides a pharmaceutical composition for treating cardiovascular disorders comprising 3-1 portion echinocystic acid and 1 portion oleanolic acid as the active components. The present invention also provides a gleditsiae extract comprising echinocystic acid and oleanolic acid of 90.0%-99.9% total weight, wherein the weight ratio of echinocystic acid and oleanolic acid is 3:1-1:3. The preparation method and use of the extract are also provided in the present invention. The pharmaceutical composition in the present invention degrades hepatotoxicity by controlling the ratio of echinocystic acid and oleanolic acid in the composition.